Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The NLR family pyrin domain containing 3 (NLRP3) inflammasome is a multi-protein complex that serves as a critical component of the innate immune system (UniProt Q96P20). It consists of the NLRP3 sensor, the ASC adapter, and pro-caspase-1. Upon activation by various stimuli—including crystalline substances like aluminum phosphate, a common vaccine adjuvant—the complex assembles to trigger the maturation and secretion of pro-inflammatory cytokines IL-1β and IL-18, as well as pyroptotic cell death (Eisenbarth et al., Nature 2008). Dysregulation of NLRP3 is linked to numerous inflammatory conditions, such as cryopyrin-associated periodic syndromes (CAPS), gout, and metabolic disorders (Mangan et al., Nature Reviews Drug Discovery 2018). Therapeutic strategies focus on inhibiting NLRP3 assembly or activity to mitigate chronic inflammation. Aluminum phosphate's role as an adjuvant is largely attributed to its ability to activate this specific inflammasome pathway, thereby enhancing the immune response to co-administered antigens (Kool et al., Journal of Experimental Medicine 2008).
NLRP3 inhibitors typically bind to the NACHT domain of the NLRP3 protein, interfering with its ATPase activity and preventing the conformational change required for oligomerization and ASC recruitment (Mangan et al., Nature Reviews Drug Discovery 2018). Aluminum phosphate acts as an activator by inducing lysosomal rupture upon phagocytosis, leading to the release of cathepsins and subsequent NLRP3 assembly (Eisenbarth et al., Nature 2008).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NLR family pyrin domain containing 3 (NLRP3) inflammasome (NLRP3).